The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Dec / Making Biopharmaceuticals in Deep Space
Manufacture Bioprocessing Biopharma Facilities & Equipment Technology & Manufacturing Sponsored

Making Biopharmaceuticals in Deep Space

NASA ultimately wants to send humans to Mars – and those humans will need medicines

By Stephanie Vine 12/03/2020 1 min read

Share

Why would medicines need to be made in space when they can be made perfectly well on Earth? Ultimately, NASA wants to send humans to Mars. It would take 3 months just to get there and they’d be stationed on Mars for a while before returning home. The voyagers would need many supplies and materials for the trip. Packing medicines for a variety of scenarios “just in case” might end up being a waste of space, which is in short supply on a spacecraft. Being able to manufacture medicines – especially those with a short shelf life – when required could make a real difference.

In this feature, experts explain exactly how it could be possible to manufacture biopharmaceutical medicines on demand in space. And if we can make medicines in space, we can make them anywhere…

A Grueling Environment: Phil Williams explains how spaceflight can affect biological processes, including pharmacokinetics and pharmacodynamics.

The Astropharmacy Concept: Lynn J Rothschild from NASA’s Ames Research Center has been involved in creating an “astropharmacy” system.

Down to Earth: Why making medicines in space can help with problems on Earth, such as cold chain (with Phil Williams).

Extraterrestrial Risk: Discussing the biosecurity risks of exo-microorganisms with Katja Schaefer.

Bringing Bioreactors to Space: Normal bioreactors do not work well in microgravity, but Richard Bonocora and colleagues have been working on a potential solution.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

Recommended

Related Content

Musings from The Power List: Ali Pashazadeh
Outsourcing Biopharma Business & Trends
Musings from The Power List: Ali Pashazadeh

August 7, 2026

7 min read

Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier

Moving Glycosylation Control Upstream
Biopharma Interviews Technology & Manufacturing
Moving Glycosylation Control Upstream

August 6, 2026

7 min read

Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.

How China Is Rewriting the Rules Global Drug Development
Development & Clinical Biopharma Interviews
How China Is Rewriting the Rules Global Drug Development

August 5, 2026

14 min read

In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development

The 10 Biggest Bottlenecks Slowing Drug Development
Development & Clinical Business & Trends Biopharma
The 10 Biggest Bottlenecks Slowing Drug Development

August 4, 2026

6 min read

Ten industry leaders from the 2026 Power List identify the scientific, clinical, regulatory, and financial barriers holding drug development back

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: